Melanoma Vaccines

Hersey, Peter; Gallagher, Stuart J.; Kirkwood, John M.; Cebon, Jonathan

doi:10.1007/978-3-030-05070-2_37

Cited by 1 publication

(2 citation statements)

References 157 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is tempting to speculate that further immunogenic tumour antigens could also be incorporated, leading to the design of a cancer vaccine that “covers all bases” in terms of heterogeneity and plasticity. As strategies are being pursued to widen the applicability of cancer immunotherapy, vaccination is now being proposed and trialled (NCT03092453) in combination with other immunotherapies, such as ICB [ 22 , 54 , 55 ]. Our study indicates that ROPN1A and ROPN1B may serve as promising candidates for such antigen-specific approaches, and therefore further studies are warranted and should be pursued to explore this.…”

Section: Discussionmentioning

confidence: 99%

“…To date, success with these treatment types has been limited. However, peptide vaccines are currently being reconsidered as combination treatments with ICB and ACT to boost immunity and broaden the cohort of responders [ 21 , 22 , 23 ]. Thus, identification of novel tumour-specific antigens continues to be of importance in the development of effective anti-cancer therapies.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Ropporin-1 and 1B Are Widely Expressed in Human Melanoma and Evoke Strong Humoral Immune Responses

Duarte

Woods

Quigley

et al. 2021

Cancers

Self Cite

View full text Add to dashboard Cite

Antibodies that block immune regulatory checkpoints (programmed cell death 1, PD-1 and cytotoxic T-lymphocyte-associated antigen 4, CTLA-4) to mobilise immunity have shown unprecedented clinical efficacy against cancer, demonstrating the importance of antigen-specific tumour recognition. Despite this, many patients still fail to benefit from these treatments and additional approaches are being sought. These include mechanisms that boost antigen-specific immunity either by vaccination or adoptive transfer of effector cells. Other than neoantigens, epigenetically regulated and shared antigens such as NY-ESO-1 are attractive targets; however, tissue expression is often heterogeneous and weak. Therefore, peptide-specific therapies combining multiple antigens rationally selected to give additive anti-cancer benefits are necessary to achieve optimal outcomes. Here, we show that Ropporin-1 (ROPN1) and 1B (ROPN1B), cancer restricted antigens, are highly expressed and immunogenic, inducing humoral immunity in patients with advanced metastatic melanoma. By multispectral immunohistochemistry, 88.5% of melanoma patients tested (n = 54/61) showed ROPN1B expression in at least 1 of 2/3 tumour cores in tissue microarrays. Antibody responses against ROPN1A and ROPN1B were detected in 71.2% of melanoma patients tested (n = 74/104), with increased reactivity seen with more advanced disease stages. Thus, ROPN1A and ROPN1B may indeed be viable targets for cancer immunotherapy, alone or in combination with other cancer antigens, and could be combined with additional therapies such as immune checkpoint blockade.

show abstract

Section: Discussionmentioning

confidence: 99%